What is the level of liabilities of Immunovant this year?
Immunovant has a debt balance of 48.61 M USD this year.
Immunovant Liabilities 2024
Immunovant Liabilities
48.61 M USD
Ticker
IMVT
ISIN
US45258J1025
In 2024, Immunovant's total liabilities amounted to 48.61 M USD, a 6.36% difference from the 45.7 M USD total liabilities in the previous year.
Immunovant Aktienanalyse
What does Immunovant do?
Immunovant ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing Immunovant's Liabilities
Immunovant's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Immunovant's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing Immunovant's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
Immunovant's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in Immunovant’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about Immunovant stock
What were the liabilities of Immunovant compared to the previous year?
The liabilities of Immunovant have increased by 6.36% increased compared to the previous year.
What are the consequences of high debt for investors of Immunovant?
High liabilities can pose a risk for investors of Immunovant, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in Immunovant?
Low liabilities mean that Immunovant has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of Immunovant affect the company?
An increase in liabilities of Immunovant can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of Immunovant affect the company?
A decrease in the liabilities of Immunovant can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of Immunovant?
Some factors that can influence the liabilities of Immunovant include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of Immunovant so important for investors?
The liabilities of Immunovant are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can Immunovant take to modify the liabilities?
To change its liabilities, Immunovant can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does Immunovant pay?
Over the past 12 months, Immunovant paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immunovant is expected to pay a dividend of 0 USD.
What is the dividend yield of Immunovant?
The current dividend yield of Immunovant is .
When does Immunovant pay dividends?
Immunovant pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Immunovant?
Immunovant paid dividends every year for the past 0 years.
What is the dividend of Immunovant?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Immunovant located?
Immunovant is assigned to the 'Health' sector.
Wann musste ich die Aktien von Immunovant kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Immunovant from 11/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/17/2024.
When did Immunovant pay the last dividend?
The last dividend was paid out on 11/17/2024.
What was the dividend of Immunovant in the year 2023?
In the year 2023, Immunovant distributed 0 USD as dividends.
In which currency does Immunovant pay out the dividend?
The dividends of Immunovant are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Immunovant
Our stock analysis for Immunovant Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunovant Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.